Zhejiang Medicine Co., Ltd. (SHA: 600216)

Market Cap	13.86B
Revenue (ttm)	8.26B
Net Income (ttm)	472.71M
Shares Out	954.81M
EPS (ttm)	0.49
PE Ratio	29.41
Forward PE	13.57
Dividend	0.15 (1.03%)
Ex-Dividend Date	Jul 10, 2024

Volume	15,757,059
Open	14.65
Previous Close	14.70
Day's Range	14.51 - 14.86
52-Week Range	7.97 - 17.50
Beta	-0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceutical products in China. The company products include synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company provides injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin products....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 6,227
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2023, 600216's revenue was 7.79 billion, a decrease of -3.96% compared to the previous year's 8.12 billion. Earnings were 429.64 million, a decrease of -20.37%.